Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

14 Sept 2022

Abstract excerpt

Apixaban is a direct oral anticoagulant, a factor Xa inhibitor, used for the prevention of ischemic stroke in patients with atrial fibrillation. Despite using recommended dosing a few patients might still experience bleeding or lack of efficacy that might be related to inappropriate drug exposure. We conducted a genome-wide association study using data from 1,325 participants in the pivotal phase three trial of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiplatelet Therapy and Cardiovascular Diseases
Share to Atrial Fibrillation Management and Outcomes
Share to Blood Coagulation and Thrombosis Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36186466
DOI: 10.3389/fgene.2022.982955

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic eventsPMID 36186466Read ↗

The impact of ABCB1, CYP3A4 and CYP3A5 gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation.Semantic proximity Read ↗

Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art ReviewSemantic proximity Read ↗

Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users.Semantic proximity Read ↗

PHARMACOGENOMICS OF NOVEL ORAL ANTICOAGULANTS (NOACs): CURRENT INSIGHTS AND FUTURE DIRECTIONSSemantic proximity Read ↗

ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban.Semantic proximity Read ↗

The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillationSemantic proximity Read ↗

Pharmacogenetics of Antiplatelets and Anticoagulants: A Report on Clopidogrel, Warfarin and DabigatranSemantic proximity Read ↗

Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up.Semantic proximity Read ↗

Pharmacogenetics of dabigatran and apixaban in association with gastrointestinal bleeding.Semantic proximity Read ↗

Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.Semantic proximity Read ↗

Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic VariantsSemantic proximity Read ↗

Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.